Predict your next investment

HEALTHCARE | Drug Development

See what CB Insights has to offer


Series A | Alive

Total Raised


Last Raised

$6M | 16 yrs ago

About Opal Therapeutics

Opal Therapeutics is an immunotherapy company focused on therapies for human immunodeficiency virus (HIV) and Hepatitis C (HCV), based on technology from the University of Melbourne.

Opal Therapeutics Headquarter Location

Melbourne, Victoria,


Latest Opal Therapeutics News

OPAL Therapeutics Inc, Immunotherapy Start Up, Raises $US6m Series A to target HIV and Hepatitis C. - GBS Venture Partners

Jun 27, 2013

OPAL Therapeutics Inc, Immunotherapy Start Up, Raises $US6m Series A to target HIV and Hepatitis C. 19 / 12 / 2005 Opal Therapeutics Inc., an immunotherapy development company targeting HIV and Hepatitis C, raises $6 million Series A financing. The company raised the funds from an international syndicate led by GBS Venture Partners, Melbourne, Australia. Other members of the syndicate are Alloy Ventures, Alta Partners, and Uniseed. OPAL is an immunotherapy development company focusing on novel therapies for HIV and Hepatitis C (HCV) based on a proprietary technology from the University of Melbourne. The company is incorporated in Delaware with preclinical operations in Australia and California. HIV and HCV are chronic viral infections inadequately treated by current therapies. Cellular immunity has an important role in the progression of both diseases, however, current treatments have generally failed to induce strong cellular immune responses. OPAL has developed a unique approach to generate high levels of cellular immune responses for the treatment of chronic infection. The Series A funding will be used initially to extend the company's intellectual property, hire staff, and manufacture the preclinical materials. It will support preclinical safety and efficacy studies and phase I human clinical trials in HIV. The founding scientist, Dr Stephen Kent, at the University of Melbourne, is a thought leader in HIV immunology. Dr Kent said his team have developed the novel treatment with outstanding effectiveness in generating strong cellular responses in extensive in vivo laboratory studies in animal models. "This funding will be used initially to refine the OPAL technology through final preclinical development and into clinical trials in humans. " Kent said. "This is a very exciting day for us. OPAL will develop a technology with the potential to provide a new treatment for a very large population of people with HIV and HCV. " Kent said. "In HIV the OPAL technology is intended to complement existing therapies and allow patients to live longer with fewer side effects and generate less drug resistance. In HCV the OPAL technology is intended to complement existing therapies and has the potential to provide an effective treatment for the large group of patients who do not respond to current therapies. " OPAL uses short peptides from the target virus to generate a strong immune response so patients can improve control of the infection. The peptides are mixed ex vivo (outside the body) with blood where they bind to immune cells and are then distributed to all parts of the body to stimulate the immune response. Kent said "It has long been known cellular immune responses have the potential to change the course of an infection. OPAL's new products have the potential to achieve what other therapies generally fail to do - and that is to generate significant cellular immunity and control viremia. "  

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Opal Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Opal Therapeutics is included in 3 Expert Collections, including Pharma Startups.


Pharma Startups

6,549 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.


Regenerative Medicine

1,708 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).



5,731 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.